Adriana Scheliga

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

Michael Pfreundschuh, Lorenz Trümper, Anders Österborg et al. · The Lancet Oncology · 2006 · 2.1K citations

Medicine, Oncology, Chemotherapy +11

Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.

B Coiffier, E.A. Osmanov, Xin Hong et al. · The Lancet Oncology · 2011 · 1.6K citations

Medicine, Hematology, Pharmacotherapy +13

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

John P. Leonard, Marek Trněný, Koji Izutsu et al. · Journal of Clinical Oncology · 2019 · 421 citations · Full text

Medicine, Immunology, Oncology +15

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study

Michael Pfreundschuh, Anthony D. Ho, Eva Cavallin‐Ståhl et al. · The Lancet Oncology · 2008 · 223 citations

Medicine, Oncology, Pharmacotherapy +11

Bleomycin-Induced Lung Injury

Tomás Reinert, Clarissa Baldotto, Frederico Arthur Pereira Nunes et al. · Journal of Cancer Research · 2013 · 156 citations · Full text

Medicine, Pathobiology, Pharmacotherapy +17